Cytochrome c oxidase 20 (COX20) deficiency, a rare mitochondrial disorder closely related to thymidine kinase 2 deficiency (TK2d), may be treatable with gene therapy, according to research demonstrating restored function and longer survival in animal models presented recently at the American Society of Gene & Cell Therapy Annual Meeting in Boston, Massachusetts.
COX20 deficiency is caused by mutations in the COX20 gene, which plays a critical role in building mitochondrial complex IV, a key component of cellular energy production. The findings suggest that replacing the missing COX20 protein could correct underlying energy problems in cells, offering hope for patients with few or no treatment options.
“This work may also contribute to uncovering mechanisms underlying other mitochondrial-related disorders,” stated the authors of this research.
Like TK2d, COX20 deficiency disrupts oxidative phosphorylation, meaning cells cannot generate energy efficiently. This group of disorders, known as mitochondrial diseases, includes conditions that affect the brain, muscles and nerves. About 33 cases of COX20 deficiency have been reported so far, with symptoms such as sensory neuropathy, ataxia (poor muscle control), speech difficulties, low muscle tone, abnormal movements and eye muscle weakness.
Read more about therapies for TK2d
To better understand the disease and test treatments, researchers developed several mouse models. Complete loss of COX20 caused death before birth, so scientists created a conditional model in which the gene could be turned off later.
These mice began losing weight around 40 days after gene suppression and developed abnormal hair growth, spinal curvature and cataracts. They also showed worsening coordination and balance, mirroring the progressive neurologic decline seen in patients. Most died within 70 to 75 days.
The research team then tested a gene replacement therapy using a modified virus, rAAV9, to deliver healthy human COX20 into cells. When given to symptomatic mice, the treatment led to rapid improvements. Within one week, animals began regaining weight, and within 20 days, motor function improved. Median survival increased to 110 days. Importantly, the therapy restored levels of key mitochondrial proteins, suggesting that energy production was repaired.
Even more striking, mice treated shortly after birth never developed symptoms at all. In a separate model where COX20 was removed only in neurons, untreated mice died around day 12, but gene therapy fully rescued survival to at least six months. Safety testing in healthy mice showed no major abnormalities, though treated animals weighed slightly less, possibly due to increased energy use.
For patients and families affected by COX20 deficiency and related disorders such as TK2d, these findings are encouraging. They suggest that early diagnosis followed by gene therapy could prevent severe disability rather than simply managing symptoms. While human trials are still needed, this approach may represent a meaningful step toward treating mitochondrial diseases at their source.
Sign up here to get the latest news, perspectives, and information about TK2d sent directly to your inbox. Registration is free and only takes a minute.
